All News

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the recruitment of Mr Jesse Thissen as Head of Biometrics, as well as the signing of the Company’s first ever two Biometrics contracts.   Contract Award The two new contracts are with a UK headquartered clinical-stage biopharmaceutical company developing immunotherapies that...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a sizeable contract extension award with an existing large pharma client.   The project builds upon the contract award announced on 13 June 2024, where the Company’s proprietary Virtual Tumour platform has been used to model the client’s targeted oncology...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a contract award with a new UK client.   The project will involve the application of population Pharmacokinetic (PK) modelling techniques using Phase 1 data to inform the Phase 2 study of a small molecule designed to treat rheumatoid arthritis....

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a contract award with a new UK client.   The project will involve the application of modelling and simulation techniques to support the development of a first-in-class bifunctional antibody therapy designed to target multiple solid tumour indiciations. More specifically, Pharmacokinetic...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the joint online publication in collaboration with Ankyra Therapeutics entitled ‘A pharmacokinetic and pharmacodynamic model of an interleukin-12 (IL-12) anchored-drug conjugate for the treatment of solid tumors’ in the Journal of Molecular Cancer Therapeutics, American Association for Cancer...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract with its long-standing client, Numab Therapeutics AG.   The project will involve the application of modelling and simulation techniques to inform pre-clinical development of a multi-specific antibody designed to activate anti-tumor immune responses for the treatment of...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is delighted to announce a contract award with a new UK-based biotech company developing antibody drug conjugates (ADCs) based therapies targeting hard-to-treat cancers.   This new project will see the Company develop a Pharmacokinetic (PK) Pharmacodynamic (PD) model to inform optimal dosing for the...